Quote this publication Share Print


Opinions on drugs - Posted on May 31 2006

Reason for request

Inclusion on the list of medicines reimbursed by National Health Insurance and approved for use by hospitals and various public services


Actual benefit


The Actual Benefit of Casodex is substantial.

Improvement in actual benefit

V (absence)

Casodex (50 mg, 150 mg) does not provide any improvement in Actual Benefit (level V) in the current management of patients with nonmetastatic prostate cancer at a locally advanced stage, as adjuvant therapy to radical prostatectomy or radiotherapy.

Contact Us

Évaluation des médicaments